MEC 20th Annual Miami Cancer Meeting 2024

MEC 20th Annual Miami Cancer Meeting 2024

Description

•  Include: 26 videos + 1 pdf, size: 3.31 GB
•  Target Audience: medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician associates
•  Sample video: contact me for sample video

 Information:

Conference Description

The areas of focus for this conference will include the current standards of care in the treatment of the aforementioned malignancies and new developments in theSe areas of Cancer care. There Will be much emphasis on molecular diagnosis and individualization of cancer therapy based on molecular profiles. There will be reviews of new chemOtherapeutic, antiangiogenic, and immUnotherapeutic agents. Topics in solid tumors and hematological malignancies will be reviewed and will include tepics in breast cancer, lung cancer, gastrointestinal (GI) malignancies, gynecologic malignancies, genitourinary (GU) cancers head and neck cancers, melanoma, and hematological malignancies such as multiple myeloma, CLL and non-Hodgkin’s-lymphoma. There will also be a special session devoted to toxicity profiles, sUpportive care, and challenges in cancer therapy.

Presentations from the latest national (AACR, ASCO, SABC, and ASH) and international forums (ESMO and WCLC) meetings Will be discussed and guidelines of cancer care using a team approach will be emphasized. The participants in the conference will have the opportunity not only to learn, review,- and understand the state-of-the-art‘ management in cancer care using a team approach but also engage in personal interaction with our panel of exports in these subjects during the questions and answers sessions.

This 3-day conference is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician associates (PA), advanced registered nurse practitioners (ARNP), oncology nurses, registered pharmacists, pharmacy technicians, and radiation therapists. General practitioners will have the benefit of reviewing standard care and new developments in cancer management. Residents in training and fellows from these, specialties are encouraged to attend.

 Topics:

• Acute Myeloid Leukemia.mp4
• B-Cell NHL (Aggressive) – Relapsed (CAR T versus Bispecifics).mp4
• B-Cell NHL (Low-Grades).mp4
• Bi-Specific Inhibitor & ADC in Lung Cancer.mp4
• Challenges in Targeting Head and Neck Squamous Cell Carcinoma.mp4
• Chronic Lymphocytic Leukemia.mp4
• Controversies in Breast Cancer Use of ctDNA to Tailor Systemic Adjuvant & Post-neoadjuvant Therapies (Part 1).mp4
• Controversies in Breast Cancer Use of ctDNA to Tailor Systemic Adjuvant & Post-neoadjuvant Therapies (Part 2).mp4
• Controversies in Lung Cancer Neoadjuvant vs Adjuvant IO in Early Stage NSCLC.mp4
• Endocrine Therapy for Early -and Late- Stages Breast Cancer Therapeutic Updates.mp4

Flyer.pdf

• Front Line Targeted Therapy in NSCLC Tyrosine Kinase Inhibitors.mp4
• HER-2 Disease Amplification, Overexpression, Mutation in Breast Cancer.mp4
• How to Handle Myelotoxicity from Chemotherapy in 2024 From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection.mp4
• Immunotherapy in Breast Cancer Now & The Future.mp4
• Immunotherapy in NSCLC First Line for Advanced Disease.mp4
• Kidney & Bladder Cancer Targeted, Immuno & Other Strategies.mp4
• Management of Malignant Hypercalcemia, Bone Metastases & Standard Precautions to Decrease Adverse Events.mp4
• Myelodysplasia De Novo and Acquired- What To Do.mp4
• New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue.mp4
• Novel Advances in Multiple Myeloma as Front-Line Therapy.mp4
• Prostate Cancer Diagnostic and Therapeutic Updates.mp4
• Small Cell Lung Cancer.mp4
• Targeted Therapy and Immunotherapy for Soft Tissue Tissue Sarcomas.mp4
• Triple Negative Breast Cancer Optimal Strategies.mp4
• Updates in Waldenstroms Macroglobulinemia.mp4
• What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others).mp4